WO2010121379A1 - Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog - Google Patents
Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog Download PDFInfo
- Publication number
- WO2010121379A1 WO2010121379A1 PCT/CA2010/000618 CA2010000618W WO2010121379A1 WO 2010121379 A1 WO2010121379 A1 WO 2010121379A1 CA 2010000618 W CA2010000618 W CA 2010000618W WO 2010121379 A1 WO2010121379 A1 WO 2010121379A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- polypeptide
- conjugate
- patient
- angiopep
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Definitions
- the invention relates to methods for the treatment of ovarian cancer.
- Ovarian cancer is a serious health problem; deaths from ovarian cancer in 2008 in the United States were estimated by the National Cancer Institute to be over 15,000, with over 21,000 new cases annually. It is the leading cause of deaths from gynecologic cancers and the fifth most common cause of cancer deaths in women. Based on these numbers, it is estimated that women have a lifetime risk of 1.39% of developing ovarian cancer.
- Ovarian cancer is difficult to diagnose early, as the early symptoms are often non-specific for the disease. Thus, only 19% of ovarian cancers are diagnosed before the cancer has spread from the ovaries; indeed, 2/3 of diagnoses occur only occur after the cancer has metastasized to distant locations in the body. Once the cancer has metastasized, the five-year relative survival rate (as compared to the population as a whole) is only 30.6%. For these reasons, more effective treatments for ovarian cancer, especially those who have metastatic cancer, are needed.
- ANG1005 a therapeutic which includes three molecules of paclitaxel conjugated to the peptide Angiopep-2 (SEQ ID NO:97). This conjugate is able to treat metastatic cancer having metastases both outside and inside the brain, even where the patient is not responsive to standard chemotherapeutic agents. Because ANG 1005 is effectively targeted to the cancer cells, it can, in certain cases, be administered at lower equivalent doses than paclitaxel by itself and retain efficacy. Likewise, because the conjugated paclitaxel of ANG 1005 can be less toxic than the unconjugated agent, ANGl 005 may also be administered in higher doses than paclitaxel alone and exhibit fewer side effects.
- the invention features a method of treating a patient (e.g., a human) having cancer originating from the ovary (e.g., an ovarian epithelial carcinoma or ovarian adenocarcinoma, or metastatic form thereof).
- a patient e.g., a human
- cancer originating from the ovary e.g., an ovarian epithelial carcinoma or ovarian adenocarcinoma, or metastatic form thereof.
- the method includes administering to the patient an effective amount of a conjugate including (a) an anticancer agent, and (b) a polypeptide including an amino acid sequence substantially identical to a polypeptide including the amino acid sequence of any of SEQ ID NOS : 1 - 105 and 107- 116 (e.g., SEQ ID NO:97), a modified form thereof (e.g., as described herein), or a fragment thereof, where the polypeptide, modified form, or fragment is conjugated to the anticancer agent.
- a conjugate including (a) an anticancer agent, and (b) a polypeptide including an amino acid sequence substantially identical to a polypeptide including the amino acid sequence of any of SEQ ID NOS : 1 - 105 and 107- 116 (e.g., SEQ ID NO:97), a modified form thereof (e.g., as described herein), or a fragment thereof, where the polypeptide, modified form, or fragment is conjugated to the anticancer agent.
- the anticancer agent is selected from the group consisting of paclitaxel, vinblastine, vincristine, etoposide, doxorubicin, cyclophosphamide, taxotere, melphalan, and chlorambucil.
- the anticancer agent is paclitaxel.
- the polypeptide includes an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to the sequence of SEQ ID NO:97.
- the polypeptide may have The conjugate may be administered in a dosage of about 1, 10, 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2500, or 3000 mg/m 2 , or any range between these numbers. In certain embodiments, the dosage is between 100 mg/m 2 and 2000 mg/m 2 or between 300 mg/m 2 and 1000 mg/m 2 .
- the conjugate may be administered by any means known in the art, e.g., intravenously, orally, intraarterially, intranasally, intraperitoneally, intramuscularly, subcutaneously, transdermally, ox per os to the patient.
- the ovarian cancer may be in any stage (e.g., Stage IA, IB, IC, HA, IIB, HC, HIA, IHB, IIIC, or IV) or any morphology grade (e.g., Grade 1, Grade 2, or Grade 3) as described herein.
- the cancer may be in one or both ovaries.
- the cancer may be confined to the interior of the ovary, or may appear on the outer surface of the ovary.
- cancer cells are found in uterus, fallopian tubes, or both.
- the cancer has spread to pelvic organs such as the colon, bladder, or rectum.
- cancer cells are found in the abdomen (e.g., visible to the naked eye (e.g., larger or smaller than 2 cm across), or visible only under a microscope).
- the cancer may also have metastasized to the lining of the abdomen or pelvis (peritoneum), organs of the abdomen such as the bowel, bladder, uterus, liver and lungs, or to the brain.
- the cancer may have metastasized to at least one location outside the ovary (e.g., to the brain, lung, or both).
- the cancer is in the lymph system.
- the patient has at least one metastasis outside the brain, lung, liver, kidney, or eye.
- the cancer may be drug resistant or include drug resistant cells (e.g., cells that expresses MDRl).
- the cancer may be or may include cells that are resistant to any chemotherapeutic agent including paclitaxel, carboplatin, cisplatin, doxorubicin, topotecan, gemcitabine, docetaxel, a taxane derivative, or any agent described herein.
- the method includes administration of a second anticancer therapy (e.g., any therapy described herein).
- the patient may have previously received another chemotherapeutic agent (e.g., paclitaxel, a platinum agent such as carboplatin, cisplatin, doxorubicin, topotecan, gemcitabine, docetaxel, or any agent described herein) and may optionally be drug resistant with respect to that therapeutic.
- the patient previously received combination carboplatin-paclitaxel therapy.
- the patient may also have risk factors for developing ovarian cancer
- the polypeptide may be of any length, for example, at least 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25, 35, 50, 75, 100, 200, or 500 amino acids. In certain embodiments, the polypeptide is 10 to 50 amino acids in length.
- the conjugate may be substantially pure.
- the polypeptide may be produced by recombinant genetic technology or chemical synthesis.
- the conjugate can be formulated with a pharmaceutically acceptable carrier.
- the polypeptide may include an amino acid sequence having the formula:
- each of Xl -X 19 is, independently, any amino acid (e.g., a naturally occurring amino acid such as Ala, Arg, Asn, Asp, Cys, GIn, GIu, GIy, His, He, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and VaI) or absent and at least one (e.g., 2 or 3) of Xl, XlO, and Xl 5 is arginine.
- a naturally occurring amino acid such as Ala, Arg, Asn, Asp, Cys, GIn, GIu, GIy, His, He, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and VaI
- X7 is Ser or Cys; or XlO and Xl 5 each are independently Arg or Lys.
- the residues from Xl through X 19, inclusive are substantially identical to any of the amino acid sequences of any one of SEQ ID NOS: 1-105 and 107-116 (e.g., Angiopep-1, Angiopep-2, Angiopep-3, Angiopep-4a, Angiopep-4b, Angiopep-5, Angiopep- 6, and Angiopep-7).
- at least one (e.g., 2, 3, 4, or 5) of the amino acids Xl -X 19 is Arg.
- the polypeptide has one or more additional cysteine residues at the N-terminal of the polypeptide, the C- terminal of the polypeptide, or both.
- the polypeptide is modified (e.g., as described herein).
- the polypeptide may be amidated, acetylated, or both. Such modifications to polypeptides may be at the amino or carboxy terminus of the polypeptide.
- the conjugates of the invention may also include peptidomimetics of any of the polypeptides described herein.
- the polypeptide may be in a multimeric form, for example, dimeric form (e.g., formed by disulfide bonding through cysteine residues).
- the polypeptide has an amino acid sequence described herein with at least one amino acid substitution (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 substitutions).
- the polypeptide may contain, for example, 1 to 12, 1 to 10, 1 to 5, or 1 to 3 amino acid substitutions, for example, 1 to 10 (e.g., to 9, 8, 7, 6, 5, 4, 3, 2) amino acid substitutions.
- the amino acid substitution(s) may be conservative or non-conservative.
- the polypeptide may have an arginine at one, two, or three of the positions corresponding to positions 1, 10, and 15 of the amino acid sequence of any of SEQ ID NO:1, Angiopep-1, Angiopep-2, Angiopep-3, Angiopep-4a, Angiopep- 4b, Angiopep-5, Angiopep-6, and Angiopep-7.
- the conjugate may specifically exclude a polypeptide including or consisting of any of SEQ ID NOS:1-105 and 107-116 (e.g., Angiopep-1, Angiopep-2, Angiopep-3, Angiopep-4a, Angiopep-4b, Angiopep-5, Angiopep-6, and Angiopep-7).
- the polypeptides and conjugates of the invention exclude the polypeptides of SEQ ID NOS: 102, 103, 104, and 105.
- the amino acid sequence has at least 35%, 40%,
- the amino acid sequence has at least 35%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity to an amino acid sequence selected from the group consisting of Angiopep-2 (SEQ ID NO:97), Angiopep-4b, Angiopep-5, Angiopep-6, and Angiopep-7 (SEQ ID NOS: 109-116).
- the amino acid sequence has at least 35%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity to an amino acid sequence of Angiopep-2 (SEQ ID NO:97).
- the amino acid sequence comprises the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-105 and 107-1 16, or a functional derivative thereof.
- the amino acid sequence is that of Angiopep-2 (SEQ ID NO:97), Angiopep-4b, Angiopep- 5, Angiopep-6, or Angiopep-7 (SEQ ID NOS: 109- 1 12).
- the amino acid sequence consists of the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-105 and 107-116, or a functional derivative thereof.
- the amino acid sequence is that of Angiopep-2 (SEQ ID NO:97), Angiopep-4b, Angiopep-5, Angiopep-6, or Angiopep-7 (SEQ ID NOS: 109-112).
- patient treating a human or non-human animal (e.g., a mammal).
- treating is meant ameliorating at least one symptom of a condition or disease in a subject having the condition or disease (e.g., a subject diagnosed with a metabolic disorder), as compared with an equivalent untreated control.
- Such reduction in the symptom e.g., a reduction in blood glucose levels
- conjugation is meant a polypeptide (e.g., those described herein) linked to an anticancer agent.
- the conjugation may be chemical in nature, such as via a linker, or genetic in nature for example by recombinant genetic technology.
- an effective amount is meant an amount of a compound required to treat or reduce ovarian cancer in a clinically relevant manner.
- a sufficient amount of an active compound used to practice the present invention for therapeutic treatment of ovarian cancer depends upon the manner of administration, the age, body weight, and extent of the cancer. Ultimately, the prescribers will decide the appropriate amount and dosage regimen.
- substantially identical is meant a polypeptide or nucleic acid exhibiting at least 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 85%, 90%, 95%, or even 99% identity to a reference amino acid or nucleic acid sequence.
- the length of comparison sequences will generally be at least 4 (e.g., at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 50, or 100) amino acids.
- the length of comparison sequences will generally be at least 60 nucleotides, preferably at least 90 nucleotides, and more preferably at least 120 nucleotides, or full length.
- gaps may be found between the amino acids of an analogs which are identical or similar to amino acids of the original polypeptide.
- the gaps may include no amino acids, one or more amino acids which are not identical or similar to the original polypeptide.
- Biologically active analogs of the vectors (polypeptides) of the invention are encompassed herewith. Percent identity may be determined, for example, with n algorithm GAP, BESTFIT, or FASTA in the Wisconsin Genetics Software Package Release 7.0, using default gap weights.
- fragment is meant a polypeptide originating from a portion of an original or parent sequence or from an analogue of said parent sequence.
- Fragments encompass polypeptides having truncations of one or more amino acids, wherein the truncation may originate from the amino terminus (N- terminus), carboxy terminus (C-terminus), or from the interior of the protein.
- a fragment may include the same sequence as the corresponding portion of the original sequence.
- Functional fragments of the vector (polypeptide) described herein are encompassed by the invention.
- Fragments may be at least 5 (e.g., at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 28, 30, 35, 40, 45, 50, 60, 75, 100, or 150) amino acids.
- Fragments of the invention may include, for example, a polypeptide of 7, 8, 9 or 10 amino acids to 18 amino acids. Fragments may contain any of the modifications described herein (e.g., acetylation, amidation, amino acid substitutions).
- a “drug resistant” cancer is meant a cancer that does not respond, or exhibits a decreased response to, one or more chemotherapeutic agents (e.g., any agent described herein).
- a cancer "determined to be drug resistant” is meant that the cancer is drug resistant, based on unresponsiveness or decreased responsiveness to a chemotherapeutic agent, or is predicted to be drug resistant based on a prognostic assay (e.g., a gene expression assay).
- a prognostic assay e.g., a gene expression assay
- FIG. 1 is a schematic diagram of the ANG 1005 structure.
- ANG 1005 includes three molecules of paclitaxel conjugated to the Angiopep-2 peptide (SEQ ID NO:97).
- Figures 2 A and 2B are images showing a CT scan of the patient's brain prior to ( Figure 2A) and following ( Figure 2B) treatment with ANG 1005.
- Figures 3A-3D are images showing a CT scan of the patient's lung prior to ( Figures 3A and 3C) and following ( Figure 3B and 3D) treatment with ANG 1005.
- Figures 4A and 4B are images showing a CT scan of the patient's abdomen, including liver, prior to ( Figure 4A) and following ( Figure 4B) treatment with ANG 1005.
- Figures 5A and 5B are images showing a CT scan of the patient's pelvis prior to ( Figure 5A) and following ( Figure 5B) treatment with ANG 1005.
- Figures 6A and 6B are graphs showing inhibition of ANG 1005 by the Angiopep-2 peptide ( Figure 6A) or by receptor associated protein (RAP) or aprotinin ( Figure 6B).
- Figure 7 is a graph showing LRP expression in various cell types and cell lines. Data is taken from the Gene Expression Atlas from the Genetics Institute of the Novartis Research Foundation (available online at http://expression.gnf.org/cgi-bin/index.cgi#Q).
- ANG 1005 Figure 1
- ANG 1005 Figure 1
- this particular patient's cancer appeared resistant to standard chemotherapeutics including docetaxel, carboplatin, gemcitabine, topotecan, and doxorubicin, as the patient's cancer continued to progress even after receiving these agents.
- ovarian cancer particularly metastatic ovarian cancer
- ovarian cancer has proven to be difficult to treat effectively, and given that such cancers often develop resistance to standard therapies
- therapeutics and therapeutic regimens capable of treating cancers originating from the ovary, particularly where the cancer has metastasized.
- a 73-year-old patient diagnosed with metastatic ovarian cancer was selected for participation in a clinical trial of ANG 1005.
- the patient was originally diagnosed in November 2006 with ovarian cancer. Prior to the clinical trial, the patient had received treatment from January 2007 through
- Taxotere ® docetaxel
- carboplatin carboplatin
- Gemzar ® gemzar ®
- Hycamtin topotecan
- the patient was again given a combination of Taxotere ® (docetaxel) and carboplatin from March 2008 until July 2008.
- Doxil ® doxorubicin
- Clinical trial results The patient described above is a participant in one of two ongoing FDA trials for the ANG1005 therapeutic.
- the status of the first clinical trial is summarized in Table 1 below. These trials were performed to determine safety of the ANG 1005.
- the first trial involved patients having various brain cancers: anaplastic oligodendroglioma (AO), oligoastrocytoma (OA), anaplastic astrocytoma (AA), and glioblastoma multiforme (GBM).
- AO anaplastic oligodendroglioma
- OA oligoastrocytoma
- AA anaplastic astrocytoma
- GBM glioblastoma multiforme
- PR Partial Response
- MR Minor Response
- SD Stable Disease
- the methods of the invention include treatment of a patient having ovarian cancer.
- Ovarian cancer starts with formation of a tumor in the ovary of a patient.
- the ovaries include three different tissues types, epithelial, germ, and stromal, from which a tumor can arise.
- Most (85-90%) ovarian cancers are derived from epithelial tissue, which are generally ovarian carcinomas or adenocarcinomas.
- Other ovarian cancers include germ cell tumors and stromal cell tumors.
- Risk factors for ovarian cancer may involve treatment of patient that has any one or more of risk factors for ovarian cancer.
- Risk factors for developing ovarian cancer include age, obesity, and family history of ovarian cancer, personal history of breast cancer, high fat diet.
- Genetic risk factors include mutations on the BRC ⁇ 1 and BRC A2 genes. Risk for ovarian cancer is reduced in individuals who have been pregnant, have taken oral contraceptives (birth control pills), and have had a tubal ligation.
- the methods of the invention may involve treatment of any stage or grade of ovarian cancer.
- Ovarian cancer is staged based on three categories: the T, N, and M categories and is further graded based on cellular morphology.
- the T categories are based on the location of cancer, i.e., whether the cancer is confined to the ovary or ovaries.
- N is evaluated based on whether the cancer has spread to the lymph nodes, and M is based on whether the cancer has spread to distant organs.
- the T category is divided into three subcategories: Tl, where the cancer is confined to one or both ovaries; T2, where the cancer extends from one or both ovaries into pelvic tissues, and T3, where the cancer is in one or both ovaries and has spread to the abdominal lining (peritoneum) outside the pelvis.
- Tl, T2, and T3 categories are further subdivided.
- Tl is divided into TIa, TIb, and Tie. In TIa stage cancer, the cancer is only inside one ovary, is not on the outside of the ovary, doesn't penetrate the tissue covering the ovary (the capsule), and is not in fluid taken from the pelvis.
- the cancer In TIb stage cancer, the cancer is inside both ovaries, but otherwise has the features of TIa stage cancer. In Tie stage cancer, the cancer is in one or both ovaries and is either on the outside of an ovary, has grown through the capsule of an ovary, or is in fluid taken from the pelvis.
- T2 is likewise divided into the subcategories T2a, T2b, and T2c.
- T2a stage cancer the cancer has metastasized to the uterus or to the fallopian tubes, but cancer cells are not found in fluid taken from the pelvis.
- T2b stage cancer the cancer has spread to pelvic tissues other than the uterus and fallopian tubes, but it is not in fluid taken from the pelvis.
- T2c stage cancer the cancer has spread to the uterus, fallopian tubes, and/or other pelvic tissues and is also in fluid taken from the pelvis.
- T3 is also divided into three subcategories: T3a, T3b, and T3c.
- T3a stage cancer the metastases can only be seen under a microscope.
- T3b stage cancer the metastases are visible, but no rumor is bigger than 2 cm.
- T3c stage cancer the metastases are larger than 2 cm.
- the N categorization is based on whether the cancer has spread to regional lymph nodes.
- the cancer is graded NO if there is no lymph node involvement and is graded Nl if cancer cells are found in the lymph nodes close to the ovarian tumor.
- the M categorization is based on whether the cancer has spread to distant organs, such as the liver, lungs, or non-regional lymph nodes. If there is no distant spread, the cancer is graded MO. If the cancer has spread to distant organs, including the inside of the liver and the lungs, it is graded Ml. Finally the cancer is graded based on its morphology, where a higher grade indicates a greater likelihood of metastasizing. Grade 1 indicates a well- differentiated tumor that appears similar to normal ovarian tissue. Grade 2 indicates a tumor that is not as well differentiated; it looks less like ovarian tissue than a Grade 1 tumor. A Grade 3 tumor is characterized as being poorly differentiated and does not look like ovarian tissue.
- stage grouping to determine the stage, expressed in Roman numerals from stage I (least advanced) to stage IV (most advanced).
- the methods of the invention may include, in addition to administration of a conjugates described herein, treatment using standard, art-recognized therapeutic options for a patient having ovarian cancer.
- the standard therapy or therapies will depend on the stage of cancer.
- the methods of the invention may also include administering a conjugate following prior treatment with one or more of the standard ovarian cancer therapies (e.g., following failure of the standard therapy).
- non-metastatic cancer e.g., Grade 1 or 2
- surgical removal of the tumor and surrounding tissue e.g., bilateral salpingo-oophorectomy with omentectomy
- Stage IA or IB disease e.g., bilateral salpingo-oophorectomy with omentectomy
- the treatment may further include intraperitoneal P-32 or radiation therapy or systemic chemotherapy based on platinums (e.g., carboplatin or cisplatin) alone or in combination with an alkylating agent.
- first line therapies include systemic chemotherapy based on platinums (e.g., carboplatin or cisplatin) with paclitaxel or administration of a nitrogen mustard (e.g., cyclophosphamide, mechlorethamine (mustine), uramustine (uracil mustard), melphalan, chlorambucil, and ifosfamide), nitrosoureas (e.g., carmustine and streptozocin), alkyl sulfonates (e.g., busulfan), or doxorubicin.
- a nitrogen mustard e.g., cyclophosphamide, mechlorethamine (mustine), uramustine (uracil mustard), melphalan, chlorambucil, and ifosfamide
- nitrosoureas e.g., carmustine and streptozocin
- alkyl sulfonates e.g., busulfan
- topotccan and hexamethylamine are FDA- approved as second line therapies.
- Other drugs used in second line therapy include doxorubicin, Doxil ® (doxorubicin HCl liposome injection), Hexalen ® (altretamine; hexamethylmelamine, Ifex ® (ifosfamide), VePesid ® (etoposide (VP-16)), 5-FU (5-fluorouracil), gemcitabine, and vinorelbine.
- doxorubicin Doxil ® (doxorubicin HCl liposome injection), Hexalen ® (altretamine; hexamethylmelamine, Ifex ® (ifosfamide), VePesid ® (etoposide (VP-16)), 5-FU (5-fluorouracil), gemcitabine, and vinorelbine.
- doxorubicin doxorubicin
- Doxil ® doxorubicin HCl lip
- the patient being treated in a method of the present invention may have a cancer that is drug resistant. Because the conjugates of the invention have activity even in cancers that have demonstrated resistance to standard chemotherapeutic agents, the methods of the invention are particularly useful in treating such drug resistant cancers.
- Drug resistance typically arises following treatment with a particular chemotherapeutic.
- Multiple drug resistance (MDR) can arise when a cell overproduces the p-glycoprotein (P-gp) efflux transporter.
- P-gp p-glycoprotein
- chemotherapeutic drugs can be P-gp substrates, including vinblastine, doxorubicin, etoposide, colchicine, and paclitaxel
- overexpression of P-gp in a cancer cell can lead to broad spectrum of resistance toward chemotherapeutic agents.
- paclitaxel conjugated to Angiopep-1 or Angiopep-2 are not P-gp substrates and thus should not be sensitive to P-gp overexpression in tumor cells; see, e.g., pages 46-47 and Figure 9A of International Application Publication WO 2007/009229.
- the drug conjugates described herein are useful in treating patients having cancer that is resistant to standard chemotherapeutic drugs.
- the methods of the invention may be especially usul in treating cancers having cells that express low density lipoprotein-related protein (LRP) receptor.
- LRP receptor is expressed on the surface of cells, and is capable of binding to various substrates including aprotinin, ⁇ -amyloid, tissue plasminogen activator (tPA), melano-transferrin, and receptor associated peptide (RAP).
- tPA tissue plasminogen activator
- RAP receptor associated peptide
- the peptides described herein were designed based on the consensus kunitz-domain sequences that act as LRP receptor ligands (see, e.g., PCT Publication No. WO 2004/060403).
- LRP ligands Uptake of the conjugates including Angiopep-1 or ⁇ ngiopep-2 is inhibited by LRP ligands, thus indicating involvement of LRP in this process.
- the LRP ligands RAP (200 nM) and aprotinin (10 ⁇ M) are capable of reducing brain uptake of an Angiopep conjugate.
- Angiopep-2 (10 or 100 ⁇ M) is similarly able to reduce uptake of the conjugates into cells ( Figures 6A and 6B).
- Ovarian cells express high levels of LRP ( Figure 7). Accordingly, cancers originating from ovarian cells are well suited for treatment using therapeutics that target LRP-expressing cells.
- a heating pad linked to YSI feedback controller device (Yellow Springs Instruments, Yellow Springs, OH, USA) was used to maintain the rat body temperature at 37 0 C.
- the PE-60 catheter was attached to a glass syringe filled with the tracer; with or without inhibitors, in a bicarbonate- buffered physiological saline (Smith QR., Pharm Biotechnol 8:285-307, 1996) mounted on a Harvard infusion pump (Harvard Biosciences, South Natick, MA, USA) maintained at 37 0 C. Dual-labeled experiments were performed for studying the brain uptake. [ 14 C]Sucrose was used as a vascular volume marker. Perfusion was started upon severing the heart to stop blood flow to the brain.
- the fluid was perfused into the common carotid artery at a rate of 5 ml/min for a period of 15-300 sec.
- the rat was decapitated and the brain was harvested.
- the left hemisphere of the brain was dissected into regions as described previously (Takasato et al., Am J Physiol 247:H484-93, 1984).
- the samples were weighed and counted using the gamma counter (Cobra 600) to determine the 125 I labeled drug.
- the LRP ligands or Angiopep peptides were co-perfused at the indicated concentrations.
- the methods of the invention may include administration of second therapeutic agent or treatment with a second therapy (e.g., a therapeutic agent or therapy that is standard in the art).
- a second therapy e.g., a therapeutic agent or therapy that is standard in the art.
- exemplary therapeutic agents include abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anakinra, anastrozole, arsenic trioxide, asparaginase, azacitidine, BCG Live, bevacuzimab, bexarotene, bleomycin, bleomycin, bortezombi, bortezomib, busulfan, busulfan, calusterone, capecitabine, carboplatin, ca ⁇ nustine, celecoxib, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cycl
- antiestrogen agents such as tamoxifen (e.g., citrate), raloxifene, toremifene, and SCH 57068.
- the methods of the invention include administration of a peptide- anticancer agent conjugate, such as those described in U.S. Patent Applications Publication Nos. 2006/0182684, and 2006/0189515, and U.S. Provisional Application No. 61/008,880, filed December 20, 2007.
- Such conjugates may include any polypeptide described herein, an agent capable of treating ovarian cancer such as paclitaxel or a paclitaxel analog (e.g., those described herein), and a linker (e.g., those described herein).
- Paclitaxel conjugates are exemplified by ANG1005, which includes the AngioPep-2 peptide (SEQ ID NO:97) conjugated to three paclitaxel molecules through ester linkages at the N-terminus, and through lysines at positions 10 and 15.
- the conjugates in certain embodiments, can cross the blood-brain barrier (BBB) or can be preferentially targeted to certain cell types, such as ovary, liver, lung, kidney, muscle cells or may be targeted to tumor cells (of any cell type described herein).
- BBB blood-brain barrier
- These agents conjugated to these peptides can exhibit increased uptake into the targeted cells, for example, by receptor- mediated endocytosis (e.g., through an LRP receptor).
- the conjugated agents may, either alternatively or in addition, exhibit increased stability or reduced expulsion from the cell (e.g., due to P-glycoprotein mediated efflux).
- Conjugates may further have activity in cancer cells that are resistant to standard chemotherapies.
- the methods of the invention can include administration a conjugate include any polypeptide described herein, for example, any of the polypeptides described in Table 4 (e.g., a polypeptide defined in any of SEQ ID NOS: 1-105 and 107-116 such as SEQ ID NOS: 1-97, 99, 100, 101, or 107-116), or any fragment, analog, derivative, or variant thereof.
- the polypeptide may have at least 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or even 100% identity to a polypeptide described herein.
- the polypeptide may have one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) substitutions relative to one of the sequences described herein. Other modifications are described in greater detail below.
- the conjugates can also feature fragments of these polypeptides (e.g., a functional fragment).
- the fragments are capable of entering or accumulating in a particular cell type (e.g., ovary, liver, lung, kidney, spleen, or muscle) or capable of crossing the BBB.
- Truncations of the polypeptide may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more amino acids from either the N-terminus of the polypeptide, the C-terminus of the polypeptide, or a combination thereof.
- Other fragments include sequences where internal portions of the polypeptide are deleted.
- Additional polypeptides may be identified by using one of the assays or methods described in U.S. Patent Application Publication No. 2006/0189515, which is hereby incorporated by reference, or by any method known in the art.
- a candidate vector may be produced by conventional polypeptide synthesis, conjugated with Taxol and administered to a laboratory animal.
- a biologically active vector may be identified, for example, based on its efficacy to increase survival of an animal injected with tumor cells and treated with the conjugate as compared to a control which has not been treated with a conjugate (e.g., treated with the unconjugated agent).
- a biologically active polypeptide may be identified based on its location in the parenchyma in an in situ cerebral perfusion assay.
- In vitro BBB assays such as the model developed by CELLIALTM Technologies, may be used to identify such vectors. Assays to determine accumulation in other tissues may be performed as well.
- Labeled conjugates of a polypeptide can be administered to an animal, and accumulation in different organs can be measured.
- a polypeptide conjugated to a detectable label e.g., a near-IR fluorescence spectroscopy label such as Cy5.5
- a detectable label e.g., a near-IR fluorescence spectroscopy label such as Cy5.5
- polypeptide can be administered to an animal, and the presence of the polypeptide in an organ can be detected, thus allowing determination of the rate and amount of accumulation of the polypeptide in the desired organ.
- the polypeptide can be labeled with a radioactive isotope (e.g., 125 I).
- the polypeptide is then administered to an animal. After a period of time, the animal is sacrificed, and the animal's organs are extracted. The amount of radioisotope in each organ can then be measured using any means known in the art.
- comparing the amount of a labeled candidate polypeptide in a particular organ without amount of labeled control the ability of the candidate polypeptide the rate or amount of accumulation of a candidate polypeptide in a particular tissue can be ascertained.
- Appropriate negative controls include any polypeptide known not be transported into a particular cell type.
- Peptide no 5 includes the sequence of SEQ ID NO 5 and is amidated at its C-terminus (see for example Fig 1 )
- Peptide No 67 includes the sequence of SEQ ID NO 67 and is amidated at its C-terminus (see for example Fig 1 )
- Peptide No 76 includes the sequence of SEQ ID NO 76 and is amidated at its C-terminus
- Peptide no 91 includes the sequence of SEQ ID NO 91 and is amidated at its C-terminus (see for example Fig 1 )
- Peptide No 107 includes the sequence of SEQ ID NO 97 and is acetylated at its N- terminus
- Peptide No 109 includes the sequence of SEQ ID NO 109 and is acetylated at its N- terminus
- Peptide No. 110 includes the sequence of SEQ ID NO:110 and is acetylated at its N- terminus.
- Angiopep-1 SEQ ID NO:67
- Angiopep-2 SEQ ID NO:97
- new vectors based on the Angiopep-1 and Angiopep- 2 sequence, were designed with variable reactive amine groups and variable overall charge. These polypeptides are shown in Table 5.
- Angiopep-3 is an acetylated form of Angiopep-2.
- 1Ac represents acetylation.
- the methods of the invention may also include administration of a conjugate that includes a polypeptide with a modification to an amino acid sequence described herein (e.g., polypeptide having a sequence described in any one of SEQ ID NOS:1-105 and 107-1 12 such as AngioPep-3, -4a, -4b, -5, - 6, or -7).
- the modification does not destroy significantly a desired biological activity.
- the modification may cause a reduction in biological activity (e.g., by at least 5%, 10%, 20%, 25%, 35%, 50%, 60%, 70%, 75%, 80%, 90%, or 95%).
- the modification has no effect on the biological activity or may increase (e.g., by at least 5%, 10%, 25%, 50%, 100%, 200%, 500%, or 1000%) the biological activity of the original polypeptide.
- the modified polypeptide may have or may optimize one or more of the characteristics of a polypeptide of the invention which, in some instance might be needed or desirable. Such characteristics include in vivo stability, bioavailability, toxicity, immunological activity, or immunological identity.
- Polypeptides used in the invention may include amino acids or sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques known in the art. Modifications may occur anywhere in a polypeptide including the polypeptide backbone, the amino acid side-chains and the amino- or carboxy-terminus. The same type of modification may be present in the same or varying degrees at several sites in a given polypeptide, and a polypeptide may contain more than one type of modification. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslational natural processes or may be made synthetically.
- modifications include pegylation, acetylation, acylation, addition of acetomidomethyl (Acm) group, ⁇ DP-ribosylation, alkylation, amidation, biotinylation, carbamoylation, carboxyethylation, esterification, covalent attachment to flavin, covalent attachment to a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of drug, covalent attachment of a marker (e.g., fluorescent or radioactive), covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, dcmethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma- carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, prote
- a modified polypeptide may further include an amino acid insertion, deletion, or substitution, either conservative or non-conservative (e.g., D-amino acids, desamino acids) in the polypeptide sequence (e.g., where such changes do not substantially alter the biological activity of the polypeptide).
- conservative or non-conservative e.g., D-amino acids, desamino acids
- Substitutions may be conservative (i.e., wherein a residue is replaced by another of the same general type or group) or non-conservative (i.e., wherein a residue is replaced by an amino acid of another type).
- a non-natural occurring amino acid may substituted for a naturally occurring amino acid (i.e., non-naturally occurring conservative amino acid substitution or a non-naturally occurring non-conservative amino acid substitution).
- Polypeptides made synthetically may include substitutions of amino acids not naturally encoded by DNA (e.g., non-naturally occurring or unnatural amino acid).
- non-naturally occurring amino acids include D- amino acids, an amino acid having an acetylaminomethyl group attached to a sulfur atom of a cysteine, a pegylated amino acid, the omega amino acids of the formula NH 2 (CH 2 ) n COOH wherein n is 2-6, neutral nonpolar amino acids, such as sarcosine, t-butyl alanine, t-butyl glycine, N-methyl isoleucine, and norleucine.
- Phenylglycine may substitute for Trp, Tyr, or Phe; citrulline and methionine sulfoxide are neutral nonpolar, cysteic acid is acidic, and ornithine is basic. Proline may be substituted with hydroxyproline and retain the conformation conferring properties.
- Analogues may be generated by substitutional mutagenesis and retain the biological activity of the original polypeptide. Examples of substitutions identified as “conservative substitutions” are shown in Table 3. If such substitutions result in a change not desired, then other type of substitutions, denominated “exemplary substitutions” in Table 6, or as further described herein in reference to amino acid classes, are introduced and the products screened. Substantial modifications in function or immunological identity are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side chain properties:
- Trp Tryptophan
- Tyrosine Tyrosine
- Phe Phenylalanine
- Histidine His
- the conjugates used in the invention may include any polypeptide analog of aprotinin known in the art.
- U.S. Patent No. 5,807,980 describes Bovine Pancreatic Trypsin Inhibitor (aprotinin)-derived inhibitors as well as a method for their preparation and therapeutic use, including the polypeptide of SEQ ID NO: 102. These polypeptides have been used for the treatment of a condition characterized by an abnormal appearance or amount of tissue factor and/or factor Villa such as abnormal thrombosis.
- U.S. Patent No. 5,780,265 describes serine protease inhibitors capable of inhibiting plasma kallikrein, including SEQ ID NO:103.
- SEQ ID NO: 106 (atgagaccag atttctgcct cgagccgccg tacactgggc cctgcaaagc tcgtatcatc cgttacttct acaatgcaaa ggcaggcctg tgtcagacct tcgtatacgg cggctgcaga gctaagcgta acaacttcaa atccgcggaa gactgcatgc gtacttgcgg tggtgcttag; Genbank accession No. X04666).
- This sequence encodes a lysine at position 16 instead of a valine, as found in SEQ ID NO:98.
- a mutation in the nucleotide sequence of SEQ ID NO: 106 may be introduced by methods known in the art to change the produce the polypeptide of SEQ ID NO:98 having a valine in position 16. Additional mutations or fragments may be obtained using any technique known in the art.
- aprotinin analogs may be found by performing a protein BLAST (Genebank: www.ncbi.nlm.nih.gov/BLAST/) using the synthetic aprotinin sequence (or portion thereof) disclosed in International Application No. PCT/CA2004/000011.
- Exemplary aprotinin analogs are found under accession Nos. CAA37967 (GI:58005) and 1405218C (GL3604747).
- polypeptides described herein or derivatives thereof are conjugated to an anticancer agent (e.g., any known in the art).
- an anticancer agent e.g., any known in the art.
- Each polypeptide may be conjugated to at least 1, 2, 3, 4, 5, 6, or 7 agents.
- each agent has at least 1, 2, 3, 4, 5, 6, 7, 10, 15, 20, or more polypeptides attached thereto.
- the conjugates of the invention may be able to promote accumulation (e.g., due to increased uptake or reduced removal) of the agent in a particular cell type or tissue such as ovary, liver, lung, kidney, spleen or muscle of a subject.
- the agent may be releasable from the vector after transport into a particular cell type or across the BBB.
- the agent can be released, for example, by enzymatic cleavage or other breakage of a chemical bond between the vector and the agent.
- the released agent may then function in its intended capacity in the absence of the vector.
- the agent is paclitaxel or a paclitaxel analog (e.g., those described herein).
- anticancer agents include abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anakinra, anastrozole, arsenic trioxide, asparaginase, azacitidine, BCG Live, bevacuzimab, bexarotene, bleomycin, bleomycin, bortezombi, bortezomib, busulfan, busulfan, calusterone, capecitabine, carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, actinomycin D, dalteparin (e.g., sodium), darbepoetin alfa, dasatinib, daun
- anticancer agents include antibodies. Conjugation of such antibodies may be accomplished using any means known in the art (e.g., using the conjugation strategies described herein). Any diagnostic or therapeutic antibody may be conjugated to one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) vectors of the invention. In addition, antibody fragments (e.g., capable of binding to an antigen) may also be conjugated to the vectors of the invention. Antibody fragments include the Fab and Fc regions, heavy chain, and light chain of an antibody (e.g., of any antibody described herein).
- Exemplary antibodies for use in diagnosis and therapy of cancer include ABX-EGF (Panitimumab), OvaRex (Oregovemab), Theragyn (pemtumomabytrrium-90), Therex, Bivatuzumab, Panorex (Edrecolomab), ReoPro (Abciximab), Bexxar (Tositumomab), MAb, idiotypic 105AD7, Anti-EpCAM (Catumaxomab), MAb lung cancer (from Cytoclonal), Herceptin (Trastuzumab), Rituxan (Rituximab), Avastin (Bevacizumab), AMD Fab (Ranibizumab), E-26 (2 nd gen.
- IgE (Omalizumab), Zevalin (Rituxan + yttrium-90) (Ibritumomab tiuxetan), Cetuximab, BEC2 (Mitumomab), IMC-ICl 1, nuC242-DMl, LymphoCide (Epratuzumab), LymphoCide Y-90, CEA-Cide (Labetuzumab), CEA-Cide Y- 90, CEA-Scan (Tc-99m-labeled arcitumomab), LeukoScan (Tc-99m-labeled sulesomab), LymphoScan (Tc-99m-labeled bectumomab), AFP-Scan (Tc-99m- labeled), HumaRAD-HN (+ yttrium-90), HumaSPECT (Votumumab), MDX- 101 (CTL A-4), MDX-210 (her
- Additional therapeutic antibodies include 5G1.1 (Ecluizumab), 5G1.1-SC (Pexelizumab), ABX-CBL (Gavilimomab), ABX-IL8, Antegren (Natalizumab), Anti-CD 1 Ia (Efalizumab), Anti-CD 18 (from Genetech), Anti-LFAl, Antova, BTI-322, CDP571, CDP850, Corsevin M, D2E7 (Adalimumab), Humira (Adalimumab), Hu23F2G (Rovelizumab), IC 14, IDEC- 114, IDEC- 131, IDEC- 151, IDEC- 152, Infliximab (Remicade), LDP-01 , LDP-02, MAK- 195F (Afelimomab), MDX-33, MDX-CD4, MEDI-507 (Siplizumab), OKT4A, OKT3 (Muromonab- CD
- Conjugation linkers The conjugate used in the invention may include using any cross-linking
- conjugation conjugation reagent or protocol known in the art, many of which are commercially available.
- protocols and reagents include, cross-linkers reactive with amino, carboxyl, sulfhydryl, carbonyl, carbohydrate and/or phenol groups. The amounts, times, and conditions of such protocols can be varied to optimize conjugation.
- Cross-linking reagents contain at least two reactive groups and are generally divided into homofunctional cross-linkers (containing identical reactive groups) and heterofunctional cross-linkers (containing non- identical reactive groups).
- the cross-linkers of the invention may be either homobifunctional and/or heterobifunctional.
- the cross-linker may incorporate a 'spacer' between the reactive moieties, or the two reactive moieties in the cross-linker may be directly linked. Bonds may include ester bonds.
- Exemplary linkers include BS 3 [Bis(sulfosuccinimidyl)suberate], NHS/EDC (N-hydroxysuccinimide and N-ethyl- (dimethylaminopropyl)carbodimide, Sulfo-EMCS ([N-e-Maleimidocaproic acidjhydrazide), SATA (N-succinimidyl-S-acetylthioacetate), and hydrazide.
- BS 3 is a homobifunctional N-hydroxysuccinimide ester that targets accessible primary amines.
- a conjugation scheme is exemplified in Fig. 2.
- NHS/EDC allows for the conjugation of primary amine groups with carboxyl groups.
- Sulfo-EMCS are heterobifunctional reactive groups (maleimide and NHS-ester) that are reactive toward sulfhydryl and amino groups.
- Amine coupling using sulfo-NHS/EDC activation may be used to cross-link therapeutic antibodies to polypeptides.
- the resulting conjugate is stable and retains the biological activity of the antibody. Moreover, it has a high conjugation capacity that can be reliably controlled and a low non-specific interaction during coupling procedures.
- SATA is reactive towards amines and adds protected sulfhydryls groups.
- the NHS-ester reacts with primary amines to form stable amide bonds.
- Sulfhydryl groups may be deprotected using hydroxylamine. Hydrazide can be used to link carboxyl groups to primary amines and may therefore be useful for linking glycoproteins.
- Small molecules such as therapeutic agents can be conjugated to polypeptides (e.g., those described herein).
- the exemplary small molecule, paclitaxel has two strategic positions (position C2' and C7) useful for conjugation.
- Conjugation of a vector or vector of the invention to paclitaxel can be performed as follows. Briefly, paclitaxel is reacted with anhydride succinic pyridine for three hours at room temperature to attach a succinyl group in position T .
- the 2'-succinyl paclitaxel has a cleavable ester bond in position 2' can simply release succinic acid. This cleavable ester bond can be further used for various modifications with linkers, if desired.
- T-O- succinyl-paclitaxel is then reacted with EDC/NHS in DMSO for nine hours at room temperature, followed by the addition of the vector or vector in Ringer/DMSO for an additional reaction time of four hours at room temperature.
- the reaction of conjugation depicted in Fig. 8 is monitored by HPLC.
- Each intermediate, such as paclitaxel, 2'-O-succinyl-paclitaxel and T- O-NHS-succinyl-paclitaxel is purified and validated using different approaches such as HPLC, thin liquid chromatography, NMR ( 13 C or 1 H exchange), melting point, mass spectrometry.
- the final conjugate is analyzed by mass spectrometry and SDS-polyacrylamide gel electrophoresis. This allows determining the number of paclitaxel molecules conjugated on each vector. Dosages
- the dosage of any conjugate or composition described herein depends on several factors, including: the administration method, the severity of the disease, whether the cancer is to be treated or prevented, and the age, weight, and health of the subject to be treated.
- a vector, conjugate, or composition may be administered to the subject in a single dose or in multiple doses.
- a compound described herein or identified using screening methods of the invention may conjugate be administered once a week for, e.g., 2, 3, 4, 5, 6, 7, 8, 10, 15, 20, or more weeks. It is to be understood that, for any particular subject, specific dosage regimes should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the composition.
- the dosage of a composition can be increased if the lower dose does not provide sufficient activity in the treatment of a disease or condition described herein (e.g., cancer). Conversely, the dosage of the composition can be decreased if the disease (e.g., cancer) is reduced or eliminated.
- a disease or condition described herein e.g., cancer
- a therapeutically effective amount of a vector, conjugate, or composition described herein may be, for example, in the range of 0.0035 ⁇ g to 20 ⁇ g/kg body weight/day or 0.010 ⁇ g to 140 ⁇ g/kg body weight/week.
- a therapeutically effective amount is in the range of 0.025 ⁇ g to 10 ⁇ g/kg, for example, at least 0.025, 0.035, 0.05, 0.075, 0.1, 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, 8.0, or 9.0 ⁇ g/kg body weight administered daily, every other day, or twice a week.
- a therapeutically effective amount may be in the range of 0.05 ⁇ g to 20 ⁇ g/kg, for example, at least 0.05, 0.7, 0.15, 0.2, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 14.0, 16.0, or 18.0 ⁇ g/kg body weight administered weekly, every other week, every three weeks or once a month.
- a therapeutically effective amount of a compound may be, for example, in the range of 0.1 mg/m 2 to 2,000 mg/m 2 administered every other day, once weekly, every other week or every three weeks.
- ANG 1005 may be administered at 50, 100, 200, 300, 400, 420, 500, 600, 650, 700, 800, or 1,000 mg/m 2 every one, two, three, four weeks, or every month or every other month.
- ANG 1005 is administered at 300 mg/m 2 or 420 mg/m 2 every three weeks.
- the therapeutically effective amount is in the range of 1000 ⁇ g/m 2 to 20,000 ⁇ g/m 2 , for example, at least 1000, 1500, 4000, or 14,000 ⁇ g/m 2 of the compound administered daily, every other day, twice weekly, weekly, or every other week.
- compositions may be by any suitable means that results in a concentration of the compound that treats ovarian cancer.
- the conjugate may be in any appropriate amount of any suitable carrier substance, and is generally present in an amount of 1-95% by weight of the total weight of the composition.
- the composition may be provided in a dosage form that is suitable for the oral, parenteral (e.g., intravenously or intramuscularly), rectal, cutaneous, nasal, vaginal, inhalant, skin (patch), topical, ocular, or intracranial administration route.
- the composition may be in the form of, e.g., tablets, capsules, pills, powders, granulates, suspensions, emulsions, solutions, gels including hydrogels, pastes, ointments, creams, plasters, drenches, osmotic delivery devices, suppositories, enemas, injectables, implants, sprays, or aerosols.
- the pharmaceutical compositions may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy, 20th edition, 2000, ed. A.R. Gennaro, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
- compositions may be formulated to release the conjugate(s) immediately upon administration or at any predetermined time or time period after administration.
- controlled release formulations which include (i) formulations that create substantially constant concentrations of the conjugate(s) within the body over an extended period of time; (ii) formulations that after a predetermined lag time create substantially constant concentrations of the conjugate(s) within the body over an extended period of time; (iii) formulations that sustain the co ⁇ jugate(s) action during a predetermined time period by maintaining a relatively constant, effective level of the conjugate(s) in the body with concomitant minimization of undesirable side effects associated with fluctuations in the plasma level of the conjugate(s) (sawtooth kinetic pattern); (iv) formulations that localize action of conjugate(s), e.g., spatial placement of a controlled release composition adjacent to or in the diseased tissue or organ; (v) formulations that achieve convenience of dosing, e.g., administering the composition once per
- controlled release is obtained by appropriate selection of various formulation parameters and ingredients, including, e.g., various types of controlled release compositions and coatings.
- the conjugate(s) is formulated with appropriate excipients into a pharmaceutical composition that, upon administration, releases the conjugate(s) in a controlled manner. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, molecular complexes, microspheres, nanoparticles, patches, and liposomes.
- the administration of a conjugate described herein or a composition containing the conjugate may be by any suitable means that results in a concentration of the compound that treats ovarian cancer.
- the conjugate may be in any appropriate amount of any suitable carrier substance, and is generally present in an amount of 1-95% by weight of the total weight of the composition.
- the composition may be provided in a dosage form that is suitable for the oral, parenteral (e.g., intravenously or intramuscularly), rectal, cutaneous, nasal, vaginal, inhalant, skin (patch), topical, ocular, or intracranial administration route.
- the composition may be in the form of, e.g., tablets, capsules, pills, powders, granulates, suspensions, emulsions, solutions, gels including hydrogels, pastes, ointments, creams, plasters, drenches, osmotic delivery devices, suppositories, enemas, injectables, implants, sprays, or aerosols.
- the pharmaceutical compositions may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy, 20th edition, 2000, ed. A.R. Gennaro, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
- compositions may be formulated to release the conjugate(s) immediately upon administration or at any predetermined time or time period after administration.
- controlled release formulations which include (i) formulations that create substantially constant concentrations of the conjugate(s) within the body over an extended period of time; (ii) formulations that after a predetermined lag time create substantially constant concentrations of the conjugate(s) within the body over an extended period of time; (iii) formulations that sustain the conjugate(s) action during a predetermined time period by maintaining a relatively constant, effective level of the conjugate(s) in the body with concomitant minimization of undesirable side effects associated with fluctuations in the plasma level of the conjugate(s) (sawtooth kinetic pattern); (iv) formulations that localize action of conjugate(s), e.g., spatial placement of a controlled release composition adjacent to or in the diseased tissue or organ; (v) formulations that achieve convenience of dosing, e.g., administering the composition once per week or
- conjugate(s) in the form of a controlled release formulation is especially preferred for conjugate(s) having a narrow absorption window in the gastrointestinal tract or a relatively short biological half-life. Any of a number of strategies can be pursued in order to obtain controlled release in which the rate of release outweighs the rate of metabolism of the conjugate(s) in question.
- controlled release is obtained by appropriate selection of various formulation parameters and ingredients, including, e.g., various types of controlled release compositions and coatings.
- the conjugate(s) is formulated with appropriate excipients into a pharmaceutical composition that, upon administration, releases the conjugate(s) in a controlled manner. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, molecular complexes, microspheres, nanoparticles, patches, and liposomes.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2759129A CA2759129C (en) | 2009-04-20 | 2010-04-20 | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
RU2011146654/15A RU2011146654A (en) | 2009-04-20 | 2010-04-20 | METHODS FOR TREATING OVARIAN CANCER USING CONJUGATED PRODUCT |
EP10766565.5A EP2421562B1 (en) | 2009-04-20 | 2010-04-20 | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
CN2010800275644A CN102510759A (en) | 2009-04-20 | 2010-04-20 | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
AU2010239069A AU2010239069B2 (en) | 2009-04-20 | 2010-04-20 | Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog |
JP2012505012A JP2012524030A (en) | 2009-04-20 | 2010-04-20 | Treatment of ovarian cancer with an anticancer agent conjugated to an angiopep-2 analog |
MX2011011023A MX2011011023A (en) | 2009-04-20 | 2010-04-20 | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog. |
ES10766565T ES2729261T3 (en) | 2009-04-20 | 2010-04-20 | Ovarian cancer treatment using an anticancer agent conjugated to an Angiopep-2 analog |
BRPI1015295A BRPI1015295A2 (en) | 2009-04-20 | 2010-04-20 | tracing ovarian cancer using an anticancer agent conjugated to an angiopep-2 analogue. |
US13/265,309 US9173891B2 (en) | 2009-04-20 | 2010-04-20 | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
ZA2011/07626A ZA201107626B (en) | 2009-04-20 | 2011-10-18 | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17104009P | 2009-04-20 | 2009-04-20 | |
US61/171,040 | 2009-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010121379A1 true WO2010121379A1 (en) | 2010-10-28 |
Family
ID=43010638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2010/000618 WO2010121379A1 (en) | 2009-04-20 | 2010-04-20 | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
Country Status (12)
Country | Link |
---|---|
US (1) | US9173891B2 (en) |
EP (1) | EP2421562B1 (en) |
JP (1) | JP2012524030A (en) |
CN (1) | CN102510759A (en) |
AU (1) | AU2010239069B2 (en) |
BR (1) | BRPI1015295A2 (en) |
CA (1) | CA2759129C (en) |
ES (1) | ES2729261T3 (en) |
MX (1) | MX2011011023A (en) |
RU (1) | RU2011146654A (en) |
WO (1) | WO2010121379A1 (en) |
ZA (1) | ZA201107626B (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8487072B2 (en) | 2006-10-19 | 2013-07-16 | Angiochem Inc. | Compounds for stimulating P-glycoprotein function and uses thereof |
WO2014026286A1 (en) * | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
WO2014071531A1 (en) * | 2012-11-12 | 2014-05-15 | Angiochem Inc. | Aprotinin-derived polypeptide-antibody conjugates |
US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
US8921314B2 (en) | 2008-10-15 | 2014-12-30 | Angiochem, Inc. | Conjugates of GLP-1 agonists and uses thereof |
US8969310B2 (en) | 2005-07-15 | 2015-03-03 | Angiochem Inc. | Potentiation of anticancer agents |
US9161988B2 (en) | 2009-07-02 | 2015-10-20 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
US9173891B2 (en) | 2009-04-20 | 2015-11-03 | Angiochem, Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
US9221867B2 (en) | 2003-01-06 | 2015-12-29 | Angiochem Inc. | Method for transporting a compound across the blood-brain barrier |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US9687561B2 (en) | 2012-08-14 | 2017-06-27 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
EP3222291A4 (en) * | 2014-10-24 | 2018-07-11 | University of Science and Technology of China | Angiopeptin for amyloid protein development and derivatives thereof |
US10980892B2 (en) | 2015-06-15 | 2021-04-20 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
EP4000613A1 (en) | 2020-11-19 | 2022-05-25 | Polyphor Ag | Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer |
WO2022106061A1 (en) | 2020-11-19 | 2022-05-27 | Polyphor Ag | Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer |
EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
CN105585614B (en) * | 2014-10-24 | 2019-06-07 | 中国科学技术大学 | Angiogenic peptide and its derivative for amyloid protein imaging |
WO2020036987A1 (en) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2597958A1 (en) * | 2005-02-18 | 2006-08-24 | Angiochem Inc. | Molecules for transporting a compound across the blood-brain barrier |
CA2614687A1 (en) * | 2005-07-15 | 2007-01-25 | Angiochem Inc. | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
CA2688344A1 (en) * | 2007-05-29 | 2008-12-04 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
Family Cites Families (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
WO1987005702A1 (en) | 1986-03-13 | 1987-09-24 | Biotechnology Australia Pty. Ltd. | Method of assay of inhibin |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
GB2208511A (en) | 1987-08-07 | 1989-04-05 | Bayer Ag | Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology |
US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US5632990A (en) | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
US5258499A (en) | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
DE3912638A1 (en) | 1989-04-18 | 1990-10-31 | Bayer Ag | GENETICALLY MANUFACTURED HOMOLOGE OF THE ALZHEIMER PROTEASE INHIBITOR, WIRSTSTAEMME AND EXPRESSION VECTORS FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS |
US5126249A (en) | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
US6475781B1 (en) | 1990-05-17 | 2002-11-05 | Dana-Farber Cancer Institute, Inc. | Trans-dominant suppressor genes for oligomeric proteins |
US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
GB9017008D0 (en) | 1990-08-02 | 1990-09-19 | Erba Carlo Spa | Process for the enzymatic preparation of basic fibroblast growth factor |
US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
US5955444A (en) | 1991-08-09 | 1999-09-21 | Massachusetts Institute Of Technology | Method of inhibiting abnormal tau hyper phosphorylation in a cell |
US5627270A (en) | 1991-12-13 | 1997-05-06 | Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
WO1994007528A1 (en) | 1992-09-25 | 1994-04-14 | Corvas International, Inc. | Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia-tissue factor complex |
EP0599303A3 (en) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
WO1994019692A1 (en) | 1993-02-18 | 1994-09-01 | The General Hospital Corporation | Alzheimer's disease therapeutics |
EP0820466A2 (en) | 1995-04-04 | 1998-01-28 | Advanced Bioconcept Inc. | Fluorescent peptides |
ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
AU5854096A (en) | 1995-05-08 | 1996-11-29 | Scios Inc. | Kunitz type protease inhibitors |
AU5908296A (en) | 1995-05-31 | 1996-12-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for targeted delivery of effector m olecules |
US5780265A (en) | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
BR9708021A (en) | 1996-03-11 | 1999-07-27 | Bayer Ag | Substantially purified protein pharmaceutical composition isolated nucleic acid sequence self-replicating protein expression vector and processes for inhibiting serine protein activity to treat a condition and prepare a protein drug |
WO1997040160A1 (en) | 1996-04-24 | 1997-10-30 | Rijksuniversiteit Te Groningen | A prokaryotic protein having functional and structural homology with the human p-glycoprotein encoded by the mdr-1 gene, nucleic acids encoding and cells expressing said protein |
JP2000509394A (en) | 1996-05-01 | 2000-07-25 | アンティバイラルズ インコーポレイテッド | Polypeptide conjugates for transporting substances across cell membranes |
DE19636889A1 (en) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastic transferrin and albumin conjugates of cytostatic compounds from the group of the anthracyclines, alkylating agents, antimetabolites and cisplatin analogues and medicaments containing them |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
EP0932390A1 (en) | 1996-10-11 | 1999-08-04 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
CA2283474A1 (en) | 1997-03-04 | 1998-09-11 | Bio-Technology General Corp. | Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
GB9705903D0 (en) | 1997-03-21 | 1997-05-07 | Elliott Gillian D | VP22 Proteins and uses thereof |
EP0975370B9 (en) | 1997-05-21 | 2004-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
US5981564A (en) | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
GB9814527D0 (en) | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
US5922754A (en) | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
US6191290B1 (en) | 1999-02-24 | 2001-02-20 | Uab Research Foundation | Taxane derivatives for targeted therapy of cancer |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
US6180607B1 (en) | 1999-08-05 | 2001-01-30 | Christopher Davies | Protein having proteinase inhibitor activity |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
EP1214292B1 (en) | 1999-09-24 | 2007-06-13 | Genentech, Inc. | Tyrosine derivatives |
US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
DE19953696A1 (en) | 1999-11-09 | 2001-05-10 | Alexander Cherkasky | Selective non-peptidic proteolytic enzyme analogue useful for the dissolution of plaques and treatment of polypeptide mediated illnesses comprises proteolytic amino acid residues bonded to a carrier molecule |
CA2355334A1 (en) | 2000-10-16 | 2002-04-16 | Procyon Biopharma Inc. | Pharmaceutical preparations and methods for inhibiting tumors |
US6919370B2 (en) | 2000-11-28 | 2005-07-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
WO2002046227A2 (en) | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
JP2004528309A (en) | 2001-03-23 | 2004-09-16 | ナプロ バイオセラピューティクス,インコーポレイテッド | Molecular complex for cancer treatment |
EP2796546B1 (en) | 2001-04-19 | 2017-08-09 | The Scripps Research Institute | Incorporation of unnatural amino acids |
WO2003102583A1 (en) | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
US20030170891A1 (en) | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
DE60234057D1 (en) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | COMPOSITIONS AND METHODS FOR MODULATING TRANSPORT BY THE BLOOD-BRAIN BARRIER |
US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
US7192921B2 (en) | 2001-11-08 | 2007-03-20 | The Burnham Institute | Peptides that home to tumor lymphatic vasculature and methods of using same |
EP1472351B1 (en) | 2002-02-07 | 2007-06-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Amino acid sequences capable of facilitating penetration across a biological barrier |
JP4188909B2 (en) | 2002-03-29 | 2008-12-03 | クレアゼン インコーポレーテッド | Cytoplasmic residual cell membrane permeation peptide and uses thereof {CytoplasmicTransductionPeptides and Usetherof} |
US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
CA2487712A1 (en) | 2002-06-28 | 2004-01-08 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
EP2314691A3 (en) | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20040102369A1 (en) | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US7319090B2 (en) | 2002-11-27 | 2008-01-15 | University Of North Carolina At Chapel Hill | Methods of treating cerebral ischemia |
SI1583562T1 (en) | 2003-01-06 | 2011-10-28 | Angiochem Inc | Angiopep-1, related compounds, and uses thereof |
US20040162284A1 (en) | 2003-02-19 | 2004-08-19 | Harris Herbert W. | Method of lowering body temperature with (S) tofisopam |
PL2368553T3 (en) | 2003-04-08 | 2015-05-29 | Progenics Pharm Inc | Pharmaceutical formulations containing methylnaltrexone |
KR101184833B1 (en) | 2003-04-08 | 2012-09-20 | 바이오템프트, 비.브이. | Compositions for mucosal and oral administration comprising HCG fragments |
EP1620544B1 (en) | 2003-04-17 | 2018-09-19 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
WO2005002515A2 (en) | 2003-06-20 | 2005-01-13 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
EP1652855A4 (en) | 2003-08-08 | 2008-11-19 | Tissue Targeting Japan Inc | Polypeptides having brain -localizing activity and uses thereof |
JP2007512001A (en) | 2003-08-28 | 2007-05-17 | バイオレクシス ファーマシューティカル コーポレイション | EPO mimetic peptides and fusion proteins |
US20050058702A1 (en) | 2003-09-17 | 2005-03-17 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
US7208174B2 (en) | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
US7638299B2 (en) | 2004-07-21 | 2009-12-29 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
KR20090006221A (en) | 2004-07-26 | 2009-01-14 | 아스테리온 리미티드 | Linkers |
EP1799826B1 (en) | 2004-09-29 | 2009-08-12 | Children's Memorial Hospital | siRNA-MEDIATED GENE SILENCING OF ALPHA SYNUCLEIN |
US9002652B1 (en) | 2005-01-27 | 2015-04-07 | Institute For Systems Biology | Methods for identifying and using organ-specific proteins in blood |
CA3054535A1 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
US7341720B2 (en) | 2005-04-06 | 2008-03-11 | Genzyme Corporation | Targeting of glycoprotein therapeutics |
WO2006124737A2 (en) | 2005-05-12 | 2006-11-23 | Tapestry Pharmaceuticals, Inc. | Molecular constructs suitable for targeted conjugates |
US8877714B2 (en) | 2005-06-14 | 2014-11-04 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof |
AU2006269879A1 (en) | 2005-07-19 | 2007-01-25 | The Board Of Trustees Of The University Of Illinois | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
GB0517092D0 (en) | 2005-08-19 | 2005-09-28 | Novartis Ag | New compositions containing taxane derivatives |
EP1934359A2 (en) | 2005-09-08 | 2008-06-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical compositions for delivery of ribonucleic acid to a cell |
WO2007035716A2 (en) | 2005-09-16 | 2007-03-29 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof |
US8142781B2 (en) | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
US20070197460A1 (en) | 2005-11-01 | 2007-08-23 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
US8039432B2 (en) | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
US8290433B2 (en) | 2007-11-14 | 2012-10-16 | Blaze Mobile, Inc. | Method and system for securing transactions made through a mobile communication device |
AR054215A1 (en) | 2006-01-20 | 2007-06-13 | Eriochem Sa | A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT |
SI2402754T2 (en) | 2006-03-06 | 2023-09-29 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
US7477504B1 (en) | 2006-03-13 | 2009-01-13 | C.P.D. Technologies, Inc. | Versatile stun glove |
CN103539857A (en) | 2006-03-30 | 2014-01-29 | 葛兰素集团有限公司 | Antibodies against amyloid-beta peptide |
JP2009543806A (en) | 2006-07-13 | 2009-12-10 | バーナム インスティテュート フォー メディカル リサーチ | Methods and compositions for targeting gC1qR / p32 |
EP2046826B1 (en) | 2006-07-24 | 2011-09-14 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
MX2009002893A (en) | 2006-09-18 | 2009-07-10 | Raptor Pharmaceutical Inc | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates. |
WO2008046228A1 (en) | 2006-10-19 | 2008-04-24 | Angiochem, Inc. | Compounds for stimulating p-glycoprotein function and uses thereof |
US20100184692A1 (en) | 2006-10-27 | 2010-07-22 | University Of Kentucky Research Foundation | Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation |
US9399675B2 (en) | 2007-02-28 | 2016-07-26 | The Board Of Regents Of The University Of Oklahoma | Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration |
KR20100015786A (en) | 2007-03-21 | 2010-02-12 | 랩터 파마슈티컬 인코포레이티드 | Cyclic receptor-associated protein(rap) peptides |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
WO2009039188A1 (en) | 2007-09-17 | 2009-03-26 | Ludwig Institute For Cancer Research Ltd | Peptides and methods for the treatment of gliomas and other cancers |
AU2008308679B2 (en) | 2007-10-02 | 2015-01-29 | Marina Biotech, Inc. | Lipopeptides for delivery of nucleic acids |
WO2009070597A2 (en) | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
CN101946001A (en) | 2007-12-20 | 2011-01-12 | 安吉奥开米公司 | Polypeptide-nucleic acid conjugates and uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
AU2009215426B2 (en) | 2008-02-21 | 2015-06-11 | Burnham Institute For Medical Research | Methods and compositions related to peptides and proteins with C-terminal elements |
RU2518240C2 (en) | 2008-04-18 | 2014-06-10 | Ангиочем Инк. | Composition based on hydrophobic agents and method for preparing it (versions) |
BRPI0920121A2 (en) | 2008-10-15 | 2019-09-24 | Angiochem Inc | etoposide and doxorubicin conjugates for drug release |
JP2012505637A (en) | 2008-10-15 | 2012-03-08 | アンジオケム,インコーポレーテッド | GLP-1 agonist conjugates and uses thereof |
BRPI0923283A2 (en) | 2008-12-05 | 2017-06-06 | Angiochem Inc | therapeutic peptide conjugates and uses thereof |
CN102272163A (en) | 2008-12-05 | 2011-12-07 | 安吉奥开米公司 | leptin and leptin analog conjugates and uses thereof |
JP5759379B2 (en) | 2008-12-05 | 2015-08-05 | アンジオケム インコーポレーテッド | Neurotensin or neurotensin analog and use thereof |
EP2373789A4 (en) | 2008-12-17 | 2012-08-29 | Angiochem Inc | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
WO2010121379A1 (en) | 2009-04-20 | 2010-10-28 | Angiochem Inc | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
US20100284921A1 (en) | 2009-05-08 | 2010-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Targeted nanoparticles for intracellular cancer therapy |
US20110111056A1 (en) | 2009-06-03 | 2011-05-12 | Dicerna Pharmaceuticals, Inc. | Peptide dicer substrate agents and methods for their specific inhibition of gene expression |
EP2440581A4 (en) | 2009-06-11 | 2013-03-27 | Angiochem Inc | Fusion proteins for delivery of gdnf and bdnf to the central nervous system |
AU2010268726A1 (en) | 2009-07-02 | 2012-01-19 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
EP3000481A3 (en) | 2009-07-14 | 2016-05-11 | Mayo Foundation for Medical Education and Research | Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier |
JP2013506697A (en) | 2009-10-06 | 2013-02-28 | アンジオケム インコーポレーテッド | Compositions and methods for delivering therapeutic agents |
US9095541B2 (en) | 2009-11-24 | 2015-08-04 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
US8530429B2 (en) | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
EP2333074A1 (en) | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
EP3338770B1 (en) | 2010-03-08 | 2023-06-07 | Sloan-Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
EP2550285B1 (en) | 2010-03-22 | 2017-07-19 | President and Fellows of Harvard College | Trioxacarcins and uses thereof |
WO2011119608A1 (en) | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
CA2796215C (en) | 2010-04-14 | 2021-05-18 | National Research Council Of Canada | Compositions and methods for brain delivery of analgesic peptides |
WO2011153642A1 (en) | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
RU2013103763A (en) | 2010-07-02 | 2014-08-10 | Ангиохем Инк. | SHORT AND CONTAINING D-AMINO ACIDS POLYEPEPTIDES FOR THERAPEUTIC CONJUGATES AND THEIR APPLICATION |
US8218280B2 (en) | 2010-07-08 | 2012-07-10 | Schneider Electric USA, Inc. | Secondary thermal sensor for primary conductors |
AU2011286407A1 (en) | 2010-08-06 | 2013-02-21 | Amgen | Use of HER3 binding agents in prostate treatment |
CN102406949B (en) | 2010-09-21 | 2013-05-29 | 复旦大学 | Target tracing multi-mode diagnostic nano imaging medicine |
WO2012037687A1 (en) | 2010-09-23 | 2012-03-29 | Angiochem Inc. | Therapeutic polypeptides and uses thereof |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2011329638C1 (en) | 2010-11-18 | 2017-04-27 | The General Hospital Corporation | Novel compositions and uses of anti-hypertension agents for cancer therapy |
CN102552928A (en) | 2010-12-19 | 2012-07-11 | 复旦大学 | Double-stage targeted drug delivery system curing brain tumor and preparation method of same |
CN103648499B (en) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
CN102614105A (en) | 2011-01-28 | 2012-08-01 | 复旦大学 | Brain targeted amphotericin B (AmB) polymer micelle administration system |
EP2680820B1 (en) | 2011-03-01 | 2022-11-02 | 2-BBB Medicines B.V. | Advanced active liposomal loading of poorly water-soluble substances |
EP2691443B1 (en) | 2011-03-28 | 2021-02-17 | Massachusetts Institute of Technology | Conjugated lipomers and uses thereof |
US20140010886A1 (en) | 2011-04-07 | 2014-01-09 | Georgia Tech Research Corporation | Compositions comprising saccharide binding moieties and methods for targeted therapy |
US20140213641A1 (en) | 2011-05-09 | 2014-07-31 | Institut Quimic De Sarria | Polymeric nanoparticles for drug delivery |
WO2013004716A1 (en) | 2011-07-04 | 2013-01-10 | Universität Basel | Peptide beads |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
SG10201606288TA (en) | 2011-08-11 | 2016-09-29 | Intellikine Llc | Kinase inhibitor polymorphs |
WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
WO2013056096A1 (en) | 2011-10-13 | 2013-04-18 | Angiochem Inc. | Polypeptide-opioid conjugates and uses thereof |
EP4074694A1 (en) | 2011-10-27 | 2022-10-19 | Massachusetts Institute Of Technology | Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof |
WO2013071272A1 (en) | 2011-11-11 | 2013-05-16 | Intellikine, Llc | Kinase inhibitor polymorphs |
WO2013078564A2 (en) | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
CN104136606A (en) | 2011-12-01 | 2014-11-05 | 安吉奥开米公司 | Targeted enzyme compounds and uses thereof |
AU2012351743B2 (en) | 2011-12-13 | 2017-07-06 | Engeneic Molecular Delivery Pty Ltd | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
US9872911B2 (en) | 2011-12-16 | 2018-01-23 | Massachusetts Institute Of Technology | Alpha-aminoamidine polymers and uses thereof |
WO2013120107A1 (en) | 2012-02-09 | 2013-08-15 | University Of Rochester | Methods and compositions for treating a subject to inhibit hearing loss |
EP2819686A4 (en) | 2012-03-02 | 2016-05-25 | Icahn School Med Mount Sinai | Variants of prothymosin alpha and methods of using same |
CA2869460C (en) | 2012-04-04 | 2018-05-15 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane |
EP4005600A1 (en) | 2012-04-26 | 2022-06-01 | Yale University | Cytotoxic-drug delivering molecules targeting hiv (cdm-hs), cytotoxic activity against the human immunodeficiency virus and methods of use |
-
2010
- 2010-04-20 WO PCT/CA2010/000618 patent/WO2010121379A1/en active Application Filing
- 2010-04-20 RU RU2011146654/15A patent/RU2011146654A/en not_active Application Discontinuation
- 2010-04-20 BR BRPI1015295A patent/BRPI1015295A2/en not_active IP Right Cessation
- 2010-04-20 AU AU2010239069A patent/AU2010239069B2/en not_active Expired - Fee Related
- 2010-04-20 CA CA2759129A patent/CA2759129C/en active Active
- 2010-04-20 MX MX2011011023A patent/MX2011011023A/en not_active Application Discontinuation
- 2010-04-20 CN CN2010800275644A patent/CN102510759A/en active Pending
- 2010-04-20 EP EP10766565.5A patent/EP2421562B1/en active Active
- 2010-04-20 ES ES10766565T patent/ES2729261T3/en active Active
- 2010-04-20 US US13/265,309 patent/US9173891B2/en not_active Expired - Fee Related
- 2010-04-20 JP JP2012505012A patent/JP2012524030A/en not_active Ceased
-
2011
- 2011-10-18 ZA ZA2011/07626A patent/ZA201107626B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2597958A1 (en) * | 2005-02-18 | 2006-08-24 | Angiochem Inc. | Molecules for transporting a compound across the blood-brain barrier |
CA2614687A1 (en) * | 2005-07-15 | 2007-01-25 | Angiochem Inc. | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
CA2688344A1 (en) * | 2007-05-29 | 2008-12-04 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
Non-Patent Citations (3)
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9221867B2 (en) | 2003-01-06 | 2015-12-29 | Angiochem Inc. | Method for transporting a compound across the blood-brain barrier |
US9713646B2 (en) | 2005-07-15 | 2017-07-25 | Angiochem Inc. | Potentiation of anticancer agents |
US8969310B2 (en) | 2005-07-15 | 2015-03-03 | Angiochem Inc. | Potentiation of anticancer agents |
US8487072B2 (en) | 2006-10-19 | 2013-07-16 | Angiochem Inc. | Compounds for stimulating P-glycoprotein function and uses thereof |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US8921314B2 (en) | 2008-10-15 | 2014-12-30 | Angiochem, Inc. | Conjugates of GLP-1 agonists and uses thereof |
US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
US9173891B2 (en) | 2009-04-20 | 2015-11-03 | Angiochem, Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
US9161988B2 (en) | 2009-07-02 | 2015-10-20 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
US20160106856A1 (en) * | 2012-08-14 | 2016-04-21 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
EP2885321A4 (en) * | 2012-08-14 | 2016-03-30 | Angiochem Inc | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
US9687561B2 (en) | 2012-08-14 | 2017-06-27 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
WO2014026286A1 (en) * | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
WO2014071531A1 (en) * | 2012-11-12 | 2014-05-15 | Angiochem Inc. | Aprotinin-derived polypeptide-antibody conjugates |
EP3222291A4 (en) * | 2014-10-24 | 2018-07-11 | University of Science and Technology of China | Angiopeptin for amyloid protein development and derivatives thereof |
US10258699B2 (en) | 2014-10-24 | 2019-04-16 | University Of Science And Technology Of China | Angiopep and derivatives thereof for imaging amyloids |
US10980892B2 (en) | 2015-06-15 | 2021-04-20 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
EP4000613A1 (en) | 2020-11-19 | 2022-05-25 | Polyphor Ag | Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer |
WO2022106061A1 (en) | 2020-11-19 | 2022-05-27 | Polyphor Ag | Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer |
EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
RU2011146654A (en) | 2013-05-27 |
ZA201107626B (en) | 2012-12-27 |
US9173891B2 (en) | 2015-11-03 |
CN102510759A (en) | 2012-06-20 |
AU2010239069A1 (en) | 2011-11-10 |
AU2010239069B2 (en) | 2015-05-14 |
EP2421562B1 (en) | 2019-03-13 |
MX2011011023A (en) | 2012-01-20 |
JP2012524030A (en) | 2012-10-11 |
CA2759129A1 (en) | 2010-10-28 |
EP2421562A4 (en) | 2014-12-10 |
CA2759129C (en) | 2018-12-11 |
EP2421562A1 (en) | 2012-02-29 |
ES2729261T3 (en) | 2019-10-31 |
BRPI1015295A2 (en) | 2016-05-31 |
US20120122798A1 (en) | 2012-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010239069B2 (en) | Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog | |
EP2164866B1 (en) | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues | |
US9365634B2 (en) | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues | |
US20150038429A1 (en) | Etoposide and doxorubicin conjugates for drug delivery | |
CA2628876A1 (en) | R-ras activity in vascular regulation | |
ES2713068T3 (en) | Derivatives of IGFBP-3 and uses thereof | |
ES2488668T3 (en) | Aprotinin-like polypeptides for administering agents conjugated therewith to tissues | |
EP3836951A1 (en) | Peptides and compositions for targeted treatment and imaging | |
EP3307326B1 (en) | Methods for the treatment of leptomeningeal carcinomatosis | |
JP2023531683A (en) | Administration and methods of use of CEBP-β antagonists | |
CN104774248A (en) | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues | |
WO2006102192A1 (en) | A factor and method to increase permeability across a biomembrane using antiproliferative factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080027564.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10766565 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2759129 Country of ref document: CA Ref document number: 2012505012 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/011023 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010239069 Country of ref document: AU Date of ref document: 20100420 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010766565 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8451/CHENP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2011146654 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13265309 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1015295 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1015295 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111019 |